UBS Group Begins Coverage on Altimmune (NASDAQ:ALT)

Investment analysts at UBS Group initiated coverage on shares of Altimmune (NASDAQ:ALT) in a report issued on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $26.00 price target on the stock. UBS Group’s price target would suggest a potential upside of 253.74% from the stock’s current price.

ALT has been the subject of a number of other research reports. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd. Finally, B. Riley reaffirmed a “buy” rating and set a $20.00 target price on shares of Altimmune in a research note on Monday, August 12th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Altimmune has an average rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Trading Down 4.3 %

Shares of ALT opened at $7.35 on Tuesday. The firm has a market cap of $522.36 million, a price-to-earnings ratio of -4.54 and a beta of 0.09. The stock has a 50 day moving average of $6.83 and a 200-day moving average of $6.85. Altimmune has a 52 week low of $2.32 and a 52 week high of $14.84.

Insider Transactions at Altimmune

In other news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the sale, the director now directly owns 41,958 shares of the company’s stock, valued at $289,510.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Altimmune

Several hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its position in Altimmune by 13.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock valued at $156,000 after buying an additional 1,821 shares during the period. Creative Planning increased its position in Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after purchasing an additional 3,132 shares during the last quarter. CANADA LIFE ASSURANCE Co acquired a new position in Altimmune in the 1st quarter worth about $44,000. TFO Wealth Partners LLC acquired a new position in Altimmune in the 1st quarter worth about $51,000. Finally, Arizona State Retirement System increased its position in Altimmune by 34.4% in the 2nd quarter. Arizona State Retirement System now owns 19,847 shares of the company’s stock worth $132,000 after purchasing an additional 5,081 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.